{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:57:14Z","timestamp":1790510234208,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The preferable route for treatment of peritoneal dialysis related peritonitis remains the intraperitoneal administration of antibiotics admixed to peritoneal dialysis fluids. It is important to know whether the administered drug is compatible with the PD fluids and its container. In the present study the compatibility of aztreonam with four commercial PDFs at storing temperatures and duration representative for storing conditions in the clinical settings was investigated. Aztreonam concentrations were determined using high-performance liquid chromatography. The antimicrobial activity of aztreonam was evaluated using an <jats:italic>E. coli<\/jats:italic> diffusion disk inhibition assay and <jats:italic>P. aeruginosa<\/jats:italic> time-kill curves. In Extraneal evaluated at 6\u2009\u00b0C, 25\u2009\u00b0C and 37\u2009\u00b0C aztreonam was stable over the whole study period of 14 days and 24\u2009hours, respectively. In Physioneal and Nutrineal aztreonam was stable at 6\u2009\u00b0C for up to 14 days. Antimicrobial activity was retained in all PD fluids over the whole study period. Aztreonam remained stable and was compatible with the PD fluids, particularly with Extraneal or Nutrineal, and no compensatory dose adjustment is needed when stored for up to 14 days at refrigeration temperature before use.<\/jats:p>","DOI":"10.1038\/s41598-020-58391-y","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T11:02:47Z","timestamp":1580814167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Compatibility of aztreonam in four commercial peritoneal dialysis fluids"],"prefix":"10.1038","volume":"10","author":[{"given":"Selma","family":"Tobudic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8149-6655","authenticated-orcid":false,"given":"Manuel","family":"Kussmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Oberm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ursli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wiesholzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Burgmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Poeppl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"Reznicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"58391_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3747\/pdi.2016.00078","volume":"36","author":"PK Li","year":"2016","unstructured":"Li, P. K. et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Perit. Dial. Int. 36, 481\u2013508, https:\/\/doi.org\/10.3747\/pdi.2016.00078 (2016).","journal-title":"Perit. Dial. Int."},{"key":"58391_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3747\/pdi.2016.00136","volume":"37","author":"SA Zelenitsky","year":"2017","unstructured":"Zelenitsky, S. A. et al. Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014. Perit. Dial. Int. 37, 170\u2013176, https:\/\/doi.org\/10.3747\/pdi.2016.00136 (2017).","journal-title":"Perit. Dial. Int."},{"key":"58391_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/0002-9343(87)90638-3","volume":"83","author":"J Bernardini","year":"1987","unstructured":"Bernardini, J., Piraino, B. & Sorkin, M. Analysis of continuous ambulatory peritoneal dialysis-related Pseudomonas aeruginosa infections. Am. J. Med. 83, 829\u2013832, https:\/\/doi.org\/10.1016\/0002-9343(87)90638-3 (1987).","journal-title":"Am. J. Med."},{"key":"58391_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2215\/CJN.00010109","volume":"4","author":"B Siva","year":"2009","unstructured":"Siva, B. et al. Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases. Clin. J. Am. Soc. Nephrol. 4, 957\u2013964, https:\/\/doi.org\/10.2215\/CJN.00010109 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"58391_CR5","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1046\/j.1523-1755.2001.00748.x","volume":"59","author":"CC Szeto","year":"2001","unstructured":"Szeto, C. C. et al. Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases. Kidney Int. 59, 2309\u20132315, https:\/\/doi.org\/10.1046\/j.1523-1755.2001.00748.x (2001).","journal-title":"Kidney Int."},{"key":"58391_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2049936117727497","volume":"5","author":"S Patolia","year":"2018","unstructured":"Patolia, S., Abate, G., Patel, N. & Frey, S. Risk factors and outcomes for multidrug-resistant Gram-negative bacilli bacteremia. Ther. Adv. Infect. Dis. 5, 11\u201318, https:\/\/doi.org\/10.1177\/2049936117727497 (2018).","journal-title":"Ther. Adv. Infect. Dis."},{"key":"58391_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/089686089101100107","volume":"11","author":"IK Cheng","year":"1991","unstructured":"Cheng, I. K., Chan, C. Y. & Wong, W. T. A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). Perit. Dial. Int. 11, 27\u201330 (1991).","journal-title":"Perit. Dial. Int."},{"key":"58391_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ki.1984.174","volume":"26","author":"JS Gerig","year":"1984","unstructured":"Gerig, J. S., Bolton, N. D., Swabb, E. A., Scheld, W. M. & Bolton, W. K. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. Kidney Int. 26, 308\u2013318 (1984).","journal-title":"Kidney Int."},{"key":"58391_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/jac\/25.1.141","volume":"25","author":"J Brown","year":"1990","unstructured":"Brown, J., Altmann, P., Cunningham, J., Shaw, E. & Marsh, F. Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis. J. Antimicrob. Chemother. 25, 141\u2013147, https:\/\/doi.org\/10.1093\/jac\/25.1.141 (1990).","journal-title":"J. Antimicrob. Chemother."},{"key":"58391_CR10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/089686088900900408","volume":"9","author":"G Fuiano","year":"1989","unstructured":"Fuiano, G., Sepe, V., Viscione, M., Nani, E. & Conte, G. Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). Perit. Dial. Int. 9, 273\u2013275 (1989).","journal-title":"Perit. Dial. Int."},{"key":"58391_CR11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/089686080902900101","volume":"29","author":"F de Vin","year":"2009","unstructured":"de Vin, F., Rutherford, P. & Faict, D. Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit. Dial. Int. 29, 5\u201315 (2009).","journal-title":"Perit. Dial. Int."},{"key":"58391_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42854-y","volume":"9","author":"M Kussmann","year":"2019","unstructured":"Kussmann, M. et al. Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. Sci. Rep. 9, 6512, https:\/\/doi.org\/10.1038\/s41598-019-42854-y (2019).","journal-title":"Sci. Rep."},{"key":"58391_CR13","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s10096-017-3051-3","volume":"36","author":"M Kussmann","year":"2017","unstructured":"Kussmann, M. et al. Compatibility of fosfomycin with different commercial peritoneal dialysis solutions. Eur. J. Clin. Microbiol. Infect. Dis. 36, 2237\u20132242, https:\/\/doi.org\/10.1007\/s10096-017-3051-3 (2017).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"58391_CR14","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3747\/pdi.2012.00326","volume":"34","author":"S Tobudic","year":"2014","unstructured":"Tobudic, S. et al. Stability of anidulafungin in two standard peritoneal dialysis fluids. Perit. Dial. Int. 34, 798\u2013802, https:\/\/doi.org\/10.3747\/pdi.2012.00326 (2014).","journal-title":"Perit. Dial. Int."},{"key":"58391_CR15","doi-asserted-by":"publisher","first-page":"CD007554","DOI":"10.1002\/14651858.CD007554.pub3","volume":"10","author":"H Htay","year":"2018","unstructured":"Htay, H. et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst. Rev. 10, CD007554, https:\/\/doi.org\/10.1002\/14651858.CD007554.pub3 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"58391_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s10096-018-3221-y","volume":"37","author":"M Kussmann","year":"2018","unstructured":"Kussmann, M. et al. Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 37, 1091\u20131098, https:\/\/doi.org\/10.1007\/s10096-018-3221-y (2018).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"58391_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2146\/ajhp170318","volume":"75","author":"W Poeppl","year":"2018","unstructured":"Poeppl, W. et al. Compatibility of linezolid with commercial peritoneal dialysis solutions. Am. J. Health Syst. Pharm. 75, 1467\u20131477, https:\/\/doi.org\/10.2146\/ajhp170318 (2018).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"58391_CR18","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1128\/AAC.46.8.2327-2332.2002","volume":"46","author":"E Viaene","year":"2002","unstructured":"Viaene, E., Chanteux, H., Servais, H., Mingeot-Leclercq, M. P. & Tulkens, P. M. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother. 46, 2327\u20132332 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 7","key":"58391_CR19","doi-asserted-by":"publisher","first-page":"S645","DOI":"10.1093\/clinids\/13.Supplement_7.S645","volume":"13","author":"M Dratwa","year":"1991","unstructured":"Dratwa, M. et al. Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis. Rev. Infect. Dis. 13(Suppl 7), S645\u2013647 (1991).","journal-title":"Rev. Infect. Dis."},{"key":"58391_CR20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/089686088900900111","volume":"9","author":"P Nikolaidis","year":"1989","unstructured":"Nikolaidis, P., Dombros, N., Alexiou, P., Balaskas, E. & Tourkantonis, A. Pharmacokinetics of aztreonam administered i.p. in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit. Dial. Int. 9, 57\u201359 (1989).","journal-title":"Perit. Dial. Int."},{"key":"58391_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/ki.2013.190","volume":"84","author":"Y Cho","year":"2013","unstructured":"Cho, Y. et al. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney Int. 84, 969\u2013979, https:\/\/doi.org\/10.1038\/ki.2013.190 (2013).","journal-title":"Kidney Int."},{"key":"58391_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3747\/pdi.2016.00018","volume":"37","author":"M Wiesholzer","year":"2017","unstructured":"Wiesholzer, M. et al. Compatibility of Meropenem with Different Commercial Peritoneal Dialysis Solutions. Perit. Dial. Int. 37, 51\u201355, https:\/\/doi.org\/10.3747\/pdi.2016.00018 (2017).","journal-title":"Perit. Dial. Int."},{"key":"58391_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1046\/j.1525-139X.2002.00103.x","volume":"15","author":"HJ Manley","year":"2002","unstructured":"Manley, H. J. & Bailie, G. R. Treatment of peritonitis in APD: pharmacokinetic principles. Semin. Dial. 15, 418\u2013421 (2002).","journal-title":"Semin. Dial."},{"issue":"4","key":"58391_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3747\/pdi.2010.00183","volume":"31","author":"Laure Peyro-Saint-Paul","year":"2011","unstructured":"Peyro Saint Paul, L. et al. Daptomycin compatibility in peritoneal dialysis solutions. Perit Dial Int 31, 492\u2013495, https:\/\/doi.org\/10.3747\/pdi.2010.00183 (2011).","journal-title":"Peritoneal Dialysis International"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58391-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58391-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58391-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T14:45:22Z","timestamp":1672670722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58391-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["58391"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-58391-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"15 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1788"}}